SOPHiA GENETICS SA SOPH
7.86 USD +0.37 (+4.94%)
At closeNov 10, 2026, 4:38 PM EST
7.86 0.00 0.00%
After hours · Nov 10, 4:38 PM ET
7.51 Day range 7.91
3.83 52-week range 8.98
- YTD
- +68.31%
- 1 year
- +80.69%
News
defenseworld.net SOPHiA GENETICS Q3 Earnings Call Highlights SOPHiA GENETICS (NASDAQ: SOPH) reported third-quarter 2026 revenue growth of 25% year over year, supported by expansion in the U.S., growing adoption of liquid biopsy testing and contributions from…
seekingalpha.com SOPHiA GENETICS SA (SOPH) Q3 2026 Earnings Call Transcript SOPHiA GENETICS SA (SOPH) Q3 2026 Earnings Call Transcript
marketbeat.com SOPHiA GENETICS Q3 Earnings Call Highlights SOPHiA GENETICS NASDAQ: SOPH reported third-quarter 2026 revenue growth of 25% year over year, supported by expansion in the U.S., growing adoption of liquid biopsy testing and contributions from…
benzinga.com Sophia Genetics Q3 2026 Earnings Call Transcript Sophia Genetics (NASDAQ:SOPH) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to…
zacks.com SOPHiA GENETICS SA (SOPH) Reports Q3 Loss, Beats Revenue Estimates SOPHiA GENETICS SA (SOPH) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.3 per share a year ago.
benzinga.com Sophia Genetics Raises FY2026 Sales Guidance from $94.000M-$96.000M to $96.000M vs $95.252M Est Sophia Genetics (NASDAQ:SOPH) raises FY2026 sales outlook from $94.000 million-$96.000 million to $96.000 million vs $95.252 million estimate.
benzinga.com Sophia Genetics Q3 EPS $(0.24) Misses $(0.18) Estimate, Sales $24.267M Beat $24.035M Estimate Sophia Genetics (NASDAQ:SOPH) reported quarterly losses of $(0.24) per share which missed the analyst consensus estimate of $(0.18) by 33.33 percent. This is a 20 percent increase over losses of…
prnewswire.com SOPHiA GENETICS Reports Third Quarter 2026 Results BOSTON and ROLLE, Switzerland, Nov. 3, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today reported financial results for the third quarter…
benzinga.com HC Wainwright & Co. Reiterates Buy on Sophia Genetics, Maintains $14 Price Target HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Sophia Genetics (NASDAQ:SOPH) with a Buy and maintains $14 price target.
benzinga.com SOPHiA GENETICS, Myriad Genetics Collaborate To Advance New Prostate Cancer-specific Genomic Instability Score Technology SOPHiA GENETICS (NASDAQ:SOPH) and Myriad Genetics, Inc., (NASDAQ: MYGN) today announce a collaboration to advance new prostate cancer-specific genomic instability score (PrGIS) technology to support…
benzinga.com HC Wainwright & Co. Maintains Buy on Sophia Genetics, Raises Price Target to $14 HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Sophia Genetics (NASDAQ:SOPH) with a Buy and raises the price target from $12 to $14.
benzinga.com BTIG Maintains Buy on Sophia Genetics, Raises Price Target to $9 BTIG analyst Mark Massaro maintains Sophia Genetics (NASDAQ:SOPH) with a Buy and raises the price target from $8 to $9.
benzinga.com Sophia Genetics Raises FY2026 Sales Guidance from $92.000M-$94.000M to $94.000M-$96.000M vs $93.403M Est Sophia Genetics (NASDAQ:SOPH) raises FY2026 sales outlook from $92.000 million-$94.000 million to $94.000 million-$96.000 million vs $93.403 million estimate.- benzinga.com Sophia Genetics Q2 EPS $(0.30) Misses $(0.20) Estimate, Sales $23.310M Beat $21.729M Estimate Sophia Genetics (NASDAQ:SOPH) reported quarterly losses of $(0.30) per share which missed the analyst consensus estimate of $(0.20) by 50 percent. This is a 9.09 percent increase over losses of…
benzinga.com SOPHiA GENETICS Announces Global Collaboration To Develop, Validate, And Deploy Two Companion Diagnostics Supporting Precision Oncology Therapies With AstraZeneca SOPHiA GENETICS (NASDAQ:SOPH) today announced a new global collaboration to develop, validate, and deploy two companion diagnostics (CDx) supporting precision oncology therapies with AstraZeneca…
benzinga.com This Charles Schwab Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday Wall Street analysts change ratings on top stocks. See full changes on analyst ratings page. SCHW, MNST, FDUS have new outlooks.
benzinga.com This Urban Outfitters Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday Top Wall Street analysts upgraded URBN, GPN, YETI. See what analysts think of SCHW stock.
benzinga.com This Crane Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday Top analysts changed outlook on top names. For all changes, incl. upgrades/downgrades/initiations, see analyst ratings page. Analysts' views on CR stock.
benzinga.com HC Wainwright & Co. Initiates Coverage On Sophia Genetics with Buy Rating, Announces Price Target of $12 HC Wainwright & Co. analyst Swayampakula Ramakanth initiates coverage on Sophia Genetics (NASDAQ:SOPH) with a Buy rating and announces Price Target of $12.
benzinga.com Stock Market Today: Dow Futures Tumble, S&P 500, Nasdaq Gains As Investors Await FOMC Decision— Amkor, La-Z-Boy In Focus (UPDATED) (Editor’s note: The future prices of benchmark tracking ETFs and the headline were updated in the story.) U.S. stock futures were mixed on Wednesday, as the Dow Jones fell, while the Nasdaq 100 and…
benzinga.com Sophia Genetics, Ormat Technologies And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session U.S. stock futures mostly higher, Nasdaq futures gain 100+ points. Sophia Genetics (SOPH) falls after pricing public offering of $50M. Other stocks decline in pre-market.
benzinga.com CarMax, Jabil And 3 Stocks To Watch Heading Into Wednesday U.S. stock futures trading higher. CarMax, Sophia Genetics, Jabil, La-Z-Boy, and Safe Bulkers in focus. La-Z-Boy shares jump 17.7% after earnings.- benzinga.com SOPHiA GENETICS Commences Ordinary Shares Offering; Terms Undisclosed SOPHiA GENETICS (NASDAQ:SOPH), a global leader in Ai-driven precision medicine, announced today the commencement of a proposed underwritten public offering of its ordinary shares. The Company also…
- benzinga.com SOPHiA GENETICS Appoints President Ross Muken As CEO, Effective July 1, Succeeding Jurgi Camblong, Who Has Been Nominated As Board Chairman SOPHiA GENETICS (NASDAQ:SOPH), a global leader in Ai-driven precision medicine, today confirmed, ahead of its 2026 Annual General Meeting (AGM) scheduled for June 18, 2026, the leadership changes…
- benzinga.com SOPHiA GENETICS Inks MoU With Memorial Sloan Kettering Cancer Center To Form JV Between Two Institutions SOPHiA GENETICS (NASDAQ: SOPH) today announced that the company has signed a Memorandum of Understanding (MOU) with Memorial Sloan Kettering Cancer Center (MSK) relating to the formation of a joint…
benzinga.com Earnings Scheduled For May 5, 2026 - benzinga.com Sophia Genetics Affirms FY2026 Sales Guidance of $92.000M-$94.000M vs $93.250M Est Sophia Genetics (NASDAQ:SOPH) affirms FY2026 sales outlook from $92.000 million-$94.000 million to $92.000 million-$94.000 million vs $93.250 million estimate.
- benzinga.com Sophia Genetics Q1 EPS $(0.27) Misses $(0.25) Estimate, Sales $21.688M Beat $20.400M Estimate Sophia Genetics (NASDAQ:SOPH) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(0.25) by 8 percent. This is a 3.85 percent decrease over losses of…
- benzinga.com SOPHiA GENETICS Announces Mount Sinai Health System To Implement Its SOPHiA DDM Platform SOPHiA GENETICS (NASDAQ:SOPH), a global leader in AI-driven precision medicine, today announced that the Mount Sinai Health System, one of the leading academic health systems in the United States,…
benzinga.com BTIG Maintains Buy on Sophia Genetics, Raises Price Target to $8 BTIG analyst Mark Massaro maintains Sophia Genetics (NASDAQ:SOPH) with a Buy and raises the price target from $7 to $8.
benzinga.com Sophia Genetics Q4 Earnings Summary & Key Takeaways - benzinga.com Sophia Genetics Sees FY2026 Sales $92.000M-$94.000M vs $88.000M Est 2026 Financial OutlookBased on information as of today, SOPHiA GENETICS is reaffirming the following guidance:Full-year revenue between $92 million and $94 million, representing approximately 20% to…
- benzinga.com Earnings Scheduled For March 3, 2026
benzinga.com A Look at Sophia Genetics's Upcoming Earnings Report - benzinga.com SOPHiA GENETICS Adds Two U.S. Healthcare Systems To Its Network To Leverage AI-Native, Cloud-Based SOPHiA DDM To Analyze Complex Genomic Data At Scale SOPHiA GENETICS (NASDAQ:SOPH), a global leader in AI-driven precision medicine, today announced the addition of two of the largest U.S. healthcare systems to its network.The two new institutions,…
- benzinga.com Guggenheim Maintains Buy on Sophia Genetics, Raises Price Target to $7 Guggenheim analyst Subbu Nambi maintains Sophia Genetics (NASDAQ:SOPH) with a Buy and raises the price target from $6 to $7.
- benzinga.com SOPHiA GENETICS Promotes Ross Muken To CEO, Effective July 2026, As Co‑Founder Jurgi Camblong Moves To Executive Chairman Role Executive Transition PlanSOPHiA GENETICS today announced the promotion of Ross Muken to Chief Executive Officer, effective July 1, 2026. Mr. Muken, who currently serves as President and has been a…
- benzinga.com SOPHiA GENETICS Expects FY26 Revenue Of $92M-$94M, up ~20%-22% YoY Full Year 2026 GuidanceBased on information as of today, SOPHiA GENETICS is providing the following FY 2026 guidance:Full year revenue between $92 million and $94 million, representing approximately…
- benzinga.com SOPHiA GENETICS Reports Preliminary Q4 Revenue Of At Least $21M, Representing Increase Of ~20% YoY; FY25 Preliminary Revenue Of ~77M, Up ~18% YoY Fourth Quarter 2025 Preliminary Unaudited Financial ResultsRevenue of at least $21 million, representing an increase of approximately 20% year-over-yearPerformed over 105,000 analyses on SOPHiA DDM™…
benzinga.com Zscaler To Rally More Than 9%? Here Are 10 Top Analyst Forecasts For Monday - benzinga.com BTIG Maintains Buy on Sophia Genetics, Raises Price Target to $7 BTIG analyst Mark Massaro maintains Sophia Genetics (NASDAQ:SOPH) with a Buy and raises the price target from $6 to $7.
benzinga.com Earnings Scheduled For November 4, 2025 - benzinga.com SOPHiA GENETICS And A.D.A.M. Innovations Partner To Launch AI-Powered Liquid Biopsy Genomic Testing And Develop Companion Diagnostic For Cancer Care In Japan - A.D.A.M. Innovations, Japan's leading private genetic testing company, and SOPHiA GENETICS (NASDAQ:SOPH), an AI technology company pioneering data-driven medicine, today announced at ESMO a…
benzinga.com 2 Under-The-Radar Health-Tech Stocks With Surging Momentum Scores Two under-the-radar health-tech stocks are seeing their Momentum scores surge in Benzinga's Edge Stock Rankings.- benzinga.com Myriad Genetics And SOPHiA GENETICS Collaborate To Develop And Provide Pharmaceutical Companies With Innovative Global Liquid Biopsy Companion Diagnostic Test Myriad Genetics (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, and SOPHiA GENETICS (NASDAQ:SOPH), an AI technology company transforming precision medicine, announced…
- benzinga.com Sophia Genetics Affirms FY2025 Sales Guidance of $72.000M-$76.000M vs $74.200M Est; Projects Adjusted EBITDA Loss Between $35M-$39M Sophia Genetics (NASDAQ:SOPH) affirms FY2025 sales outlook from $72.000 million-$76.000 million to $72.000 million-$76.000 million vs $74.200 million estimate.
- benzinga.com Sophia Genetics Q2 EPS $(0.33) Misses $(0.23) Estimate, Sales $18.323M Beat $17.480M Estimate Sophia Genetics (NASDAQ:SOPH) reported quarterly losses of $(0.33) per share which missed the analyst consensus estimate of $(0.23) by 43.48 percent. This is a 43.48 percent decrease over losses of…
- benzinga.com Earnings Scheduled For August 5, 2025
- benzinga.com Earnings Scheduled For May 6, 2025
- benzinga.com Earnings Scheduled For March 4, 2025